![Sample our Behavioral Sciences journals, sign in here to start your access, latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/110801/TOC-Subject-Sample-2021-Behavioral-Sciences.jpg"})
Abstract
Jan-Uwe Claas and Mark Suett speak to Henry Ireland, Senior Drug Evaluations Editor: Dr Jan-Uwe Claas, General Manager, Grϋnenthal UK Ltd, and Dr Mark Suett, Interim Medical Director, discuss Grϋnenthal’s role in pain management, the current barriers to improving treatment in the UK and the supporting role the company plays in advancing this field. Grünenthal UK Ltd is a subsidiary of Grünenthal GmbH, based in Aachen, Germany.
KEYWORDS:
Disclaimer
The opinions expressed in this interview are those of the interviewees and do not necessarily reflect the views of Future Medicine Ltd.
Financial & competing interests disclosure
JU Claas and M Suett are employees of Grϋnenthal UK Ltd. Grϋnenthal UK Ltd owns rights to products discussed within this interview. JU Claas and M Suett have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.